ABSTRACTS - World Psychiatric Association
ABSTRACTS - World Psychiatric Association
ABSTRACTS - World Psychiatric Association
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
PO1.134.<br />
VALPROATE-RISPERIDONE VS. VALPROATE-<br />
LITHIUM COMBINATION IN ACUTE MANIA<br />
M. Barekatain, A. Fatemi, M. Salehi<br />
Isfahan University of Medical Sciences, Isfahan, Iran<br />
We evaluated the efficacy of valproate plus risperidone vs. valproate<br />
plus lithium combination in the treatment of acute mania. In a 2-week,<br />
randomized, double-blind, parallel group study, 46 acute manic<br />
patients according to DSM-IV criteria were randomly assigned to<br />
receive the combination of valproate 20 mg/kg/day plus risperidone 2-<br />
4 mg/day (n=23) or lithium 600-1200 mg/day (n=23). The assessment<br />
of efficacy was made using the Young Mania Rating Scale (YMRS) and<br />
the Clinical Global Impression-Severity (CGI-S) and Improvement<br />
(CGI-I) scale. Other effectiveness measures included YMRS response<br />
(YMRS reduction >50%) and YMRS remission (YMRS total score<br />
£12). In each group, 16 of 23 patients (70%) completed the study.<br />
YMRS response, CGI-Improvement, and reduction in total scores of<br />
YMRS and CGI-S were significantly greater in the valproate-risperidone<br />
than in the valproate-lithium group (p=0.006, p=0.015, p=0.004,<br />
and p=0.007, respectively). There was no significant difference concerning<br />
YMRS remission (p=0.073). The YMRS total score on days 4,<br />
8 and 14 of trial was lower in the valproate-risperidone than in the valproate-lithium<br />
group (p=0.017, p=0.005, and p=0.004, respectively).<br />
The rate of adverse events and the mean weight gain in the two groups<br />
were not statistically different. These data suggest that, in acute manic<br />
patients, the valproate-lithium and the valproate-risperidone combinations<br />
are both effective, but the valproate-risperidone combination<br />
has a more significant impact.<br />
PO1.135.<br />
EFFICACY OF LAMOTRIGINE AS MONOTHERAPY<br />
IN PATIENTS WITH BIPOLAR I DISORDER<br />
S. Uzun, O. Kozumplik, M. Jakovljevic, D. Ljubicic<br />
University Department, Vrapce <strong>Psychiatric</strong> Hospital; University<br />
Department, Clinical Hospital Zagreb; School of Medicine,<br />
University of Zagreb, University Department, Clinical Hospital<br />
Rijeka; School of Medicine, University of Rijeka, Croatia<br />
The study was aimed to explore the efficacy of lamotrigine as<br />
monotherapy in patients with bipolar I disorder. The sample included<br />
19 patients (8 males and 11 females, aged 18-65 years), with a diagnosis<br />
of bipolar I disorder according to the DSM-IV-TR. All patients<br />
were outpatients. This was the first treatment with lamotrigine for all<br />
patients. Patients were switched to lamotrigine due to side effects of<br />
previous treatment and/or patient’s request. The Clinical Global<br />
Impression (CGI), Young Mania Rating Scale (YMRS) and Montgomery-Asberg<br />
Depression Scale (MADRAS) were used in order to<br />
assess efficacy of the therapy. Also, Patient’s Preference Scale (PPS)<br />
was used in order to evaluate patients’ satisfaction with therapy. The<br />
first assessment was made prior to initiation of the treatment. The following<br />
assessments were made every two weeks. The period of investigation<br />
was three months. Results were statistically analyzed using<br />
methods of descriptive statistics and chi-square test. Statistical significance<br />
was set to p